Condition
IPF clinical trials and research
As of November 12, 2026, Find a Trial lists 7 IPF clinical trials that are recruiting, at sites in 7 countries (most in Turkey (Türkiye) (1), South Korea (1), Italy (1)). By phase: Phase 2 (1), Phase 1 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 7Clinical trials
- 7Countries
Newest IPF clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Photon-counting CT vs standard HRCT to help diagnose IPF and other ILDs | — | Rozzano, Italy | Recruiting | Aug 27, 2026 |
| Single-dose safety and pharmacokinetics of HW241045 in healthy adults | Phase 1 | Beijing | Recruiting | Mar 4, 2026 |
| Evaluating SB17170 in patients with idiopathic pulmonary fibrosis | Phase 2 | Goyang and 4 other locations | Recruiting | Dec 24, 2024 |
| Identifying biomarkers for progressive pulmonary fibrosis in lung disease patients | — | Amsterdam, North Holland | Recruiting | Oct 16, 2024 |
| Exploring the links between sleep hygiene, muscle loss, and brain function in lung disease | — | Jōyō, Kyoto | Recruiting | Jan 14, 2022 |
| Telerehabilitation for patients with idiopathic pulmonary fibrosis | — | Istanbul, Zeytinburnu | Recruiting | Jan 13, 2022 |
| Investigating the link between laryngopharyngeal reflux and idiopathic pulmonary fibrosis | — | Denver, Colorado | Recruiting | Feb 1, 2018 |
All recruiting trials (7)
-
Photon-counting CT vs standard HRCT to help diagnose IPF and other ILDs
This study tests whether photon-counting CT can improve identifying IPF and other ILDs compared with standard HRCT for patients discussed in multidisciplinary teams.
-
Single-dose safety and pharmacokinetics of HW241045 in healthy adults
This trial will test single ascending doses of HW241045 in healthy adults (18–55) to see if the drug is safe, well tolerated, and how it is processed by the body.
-
Evaluating SB17170 in patients with idiopathic pulmonary fibrosis
This study is testing a new drug called SB17170 to see if it can help adults with moderate to severe idiopathic pulmonary fibrosis breathe better over 12 weeks.
-
Identifying biomarkers for progressive pulmonary fibrosis in lung disease patients
This study is trying to find early signs that can help predict if adults with certain lung diseases will develop progressive pulmonary fibrosis over the next five years.
-
Exploring the links between sleep hygiene, muscle loss, and brain function in lung disease
This study looks at how good or bad sleep affects muscle loss and brain function in people with lung diseases like COPD and IPF.
-
Telerehabilitation for patients with idiopathic pulmonary fibrosis
This study is testing two different online exercise programs to see which one helps people with idiopathic pulmonary fibrosis feel better after 8 weeks of workouts.
-
Investigating the link between laryngopharyngeal reflux and idiopathic pulmonary fibrosis
This study is testing if a new way to measure throat reflux can help doctors understand how it affects people with idiopathic pulmonary fibrosis.
Related topics
Quick answers
How many IPF clinical trials are recruiting right now?
7, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 7 countries. The most sites are in Turkey (Türkiye) (1 trial), South Korea (1 trial), Italy (1 trial), Japan (1 trial), Netherlands (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 2: 1, Phase 1: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.